Upon ligand binding, BMPR1A forms a receptor complex consisting of two type II and two type I transmembrane Ser/Thr kinases. The type I receptors are activated by the type II receptors by using a phosphorylation mechanism, and subsequently bind SMAD transcriptional regulators. Defects in BMPR1A are the cause of juvenile polyposis syndrome, Cowden disease and hereditary mixed polyposis syndrome 2, which lead to gastrointestinal, breast, thyroid, endometrial and colon cancers.
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease
Signaling Molecules and Interaction
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
Bone morphogenetic protein receptor type IA; Serine/threonine-protein kinase receptor R5; SKR5; Activin receptor-like kinase 3; ALK-3; CD292 antigen; BMPR1A; ACVRLK3
The synthetic peptide used to raise the antibody Cat. No. 200151 is selected from a sequence within the N-term region of human BMPR1A. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.